Inhaled insulin.

Peter Richardson, MannKind ‘s Chief Scientific Officer. 3 trials.. Said Dr. Reports Positive Results from Final Two Pivotal Phase 3 clinical trials in type 1 and type 2 diabetes – MannKind Corporation : known to the primary endpoints of the last two Phase 3 trials AFRESATM the company meets ultra rapid acting product, inhaled insulin. The company expects to publish more details of the top-line data from these studies in patients with type 1 and type 2 diabetes by mid-December. ‘We are very pleased with the positive results from this, the last of the three phase – studies 3 – known We are looking forward to more complete data, including analysis of the secondary endpoints, as it becomes available, are expected before the end of this year.

Study 030 compared with the pulmonary safety of meal – time inhalation of AFRESA compared to usual care in over 2000 patients with type-1 and type – 2 diabetes The study met its primary endpoint: After two years of treatment, no adverse effects on the patients the lungs AFRESA treated group observed.Is also working on this study, neurologists Zbigniew Wszolek, and Ryan Uitti, from the Mayo Clinic in Florida, of study co-lead authors be D at the Philipps – University of, Marburg, Germany, of University of Pittsburgh School of Medicine., the Children hospital of Philadelphia, Justus-Liebig – University D at Giessen, Germany;? and the University of Pennsylvania School of Medicine.

‘While we have a long way to from a fresh treatment is, this new research. Researcher researchers the understanding to the understanding these tragic illness ‘.

Other entries from category "laboratory":

Random entries